Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 8/20 | 0.60 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.60 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.60 |
| ▸ | HTR2A | P28223 | 5/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.43 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.40 |
| ▸ | HTR2C | P28335 | 1/20 | 0.37 |
| ▸ | HTR2B | P41595 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL327527 | 0.84 | SLC6A4 (0.46) | SLC6A4SLC6A2SLC6A3KCNH2HRH3 | |
| SCHEMBL322766 | 0.83 | KCNH2 (0.47) | SLC6A4SLC6A2SLC6A3HTR2AKCNH2 | |
| SCHEMBL2301845 | 0.76 | SLC6A4 (1.00) | SLC6A4SLC6A2SLC6A3KCNH2 | |
| SCHEMBL320800 | 0.75 | HRH3 (0.56) | SLC6A4SLC6A2SLC6A3KCNH2HRH3 | |
| SCHEMBL321264 | 0.75 | SLC6A2 (0.54) | SLC6A4SLC6A2SLC6A3HRH3 | |
| Hydrochloric Acid SCHEMBL30357916 | 0.75 | SLC6A4 (0.96) | SLC6A4SLC6A2SLC6A3KCNH2 | |
| Hydrochloric Acid SCHEMBL5218770 | 0.75 | SLC6A4 (0.96) | SLC6A4SLC6A2SLC6A3KCNH2 | |
| SCHEMBL13766290 | 0.73 | SLC6A2 (0.51) | SLC6A4SLC6A2SLC6A3HTR2CHTR2B | |
| SCHEMBL23897956 | 0.72 | SLC6A2 (0.72) | SLC6A4SLC6A2SLC6A3 | |
| SCHEMBL14311996 | 0.72 | SLC6A2 (0.72) | SLC6A4SLC6A2SLC6A3KCNH2HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2590969-B1 | Therapeutic agents 976 | ASTRAZENECA AB (SE) | 2014-10-15 | — | — | EP | disclosed |
| EP-2590969-B1 | Therapeutic agents 976 | ASTRAZENECA AB (SE) | 2014-10-15 | — | — | EP | disclosed |
| US-8546375-B2 | (3-(4-(aminomethyl)phenoxy or phenylthio)azetidin-1-yl)(5-phenyl-1,3,4-oxadiazol-2-yl)methanone compounds | ASTRAZENECA AB (SE) | 2013-10-01 | — | — | US | disclosed |
| US-8546375-B2 | (3-(4-(aminomethyl)phenoxy or phenylthio)azetidin-1-yl)(5-phenyl-1,3,4-oxadiazol-2-yl)methanone compounds | ASTRAZENECA AB (SE) | 2013-10-01 | — | — | US | disclosed |
| EP-2590969-A2 | THERAPEUTIC AGENTS 976 | AstraZeneca AB (SE) | 2013-05-15 | — | — | EP | disclosed |
| WO-2012004588-A2 | THERAPEUTIC AGENTS 976 | ASTRAZENECA AB (SE) | 2012-01-12 | — | — | WO | disclosed |
| WO-2012004588-A2 | THERAPEUTIC AGENTS 976 | ASTRAZENECA AB (SE) | 2012-01-12 | — | — | WO | disclosed |
| US-20120010189-A1 | (3-(4-(AMINOMETHYL)PHENOXY OR PHENYLTHIO)AZETIDIN-1-YL)(5-PHENYL-1,3,4-OXADIAZOL-2-YL)METHANONE COMPOUNDS | ASTRAZENECA AB (SE) | 2012-01-12 | — | — | US | disclosed |
| US-20120010189-A1 | (3-(4-(AMINOMETHYL)PHENOXY OR PHENYLTHIO)AZETIDIN-1-YL)(5-PHENYL-1,3,4-OXADIAZOL-2-YL)METHANONE COMPOUNDS | ASTRAZENECA AB (SE) | 2012-01-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120010189-A1 | (3-(4-(AMINOMETHYL)PHENOXY OR PHENYLTHIO)AZETIDIN-1-YL)(5-PHENYL-1,3,4-OXADIAZOL-2-YL)METHANONE COMPOUNDS | TYR, MC2R, MC1R | SLC6A4 293/4885SLC6A2 345/4885SLC6A3 189/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.